JP2010525044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010525044A5 JP2010525044A5 JP2010504834A JP2010504834A JP2010525044A5 JP 2010525044 A5 JP2010525044 A5 JP 2010525044A5 JP 2010504834 A JP2010504834 A JP 2010504834A JP 2010504834 A JP2010504834 A JP 2010504834A JP 2010525044 A5 JP2010525044 A5 JP 2010525044A5
- Authority
- JP
- Japan
- Prior art keywords
- product
- treatment
- progestin
- muscle loss
- megestrol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 5
- 229940124748 beta 2 agonist Drugs 0.000 claims 5
- 210000003205 muscle Anatomy 0.000 claims 5
- 239000000583 progesterone congener Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 229960001786 megestrol Drugs 0.000 claims 4
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical group C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0707931A GB0707931D0 (en) | 2007-04-24 | 2007-04-24 | New Therapeutic use |
| GB0707930.4 | 2007-04-24 | ||
| GB0707930A GB0707930D0 (en) | 2007-04-24 | 2007-04-24 | New therapeutic use |
| GB0707931.2 | 2007-04-24 | ||
| GB0710101A GB0710101D0 (en) | 2007-05-25 | 2007-05-25 | New Therapeutic use |
| GB0710101.7 | 2007-05-25 | ||
| PCT/GB2008/001452 WO2008129308A2 (en) | 2007-04-24 | 2008-04-24 | Drug combination and its use in the treatment of muscle loss |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010525044A JP2010525044A (ja) | 2010-07-22 |
| JP2010525044A5 true JP2010525044A5 (enExample) | 2011-05-06 |
| JP5627452B2 JP5627452B2 (ja) | 2014-11-19 |
Family
ID=39639100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010504834A Expired - Fee Related JP5627452B2 (ja) | 2007-04-24 | 2008-04-24 | 筋肉減少の治療に使用される薬剤の組合せ |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8653052B2 (enExample) |
| EP (1) | EP2155180B1 (enExample) |
| JP (1) | JP5627452B2 (enExample) |
| KR (1) | KR101546977B1 (enExample) |
| CN (2) | CN101730547A (enExample) |
| AU (1) | AU2008240379B2 (enExample) |
| BR (1) | BRPI0810461A2 (enExample) |
| CA (1) | CA2721739C (enExample) |
| DK (1) | DK2155180T3 (enExample) |
| EA (1) | EA018918B1 (enExample) |
| ES (1) | ES2592289T3 (enExample) |
| HK (1) | HK1202262A1 (enExample) |
| IL (1) | IL201426A (enExample) |
| MX (1) | MX2009011294A (enExample) |
| NZ (1) | NZ580975A (enExample) |
| WO (1) | WO2008129308A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE457169T1 (de) | 1998-10-15 | 2010-02-15 | Imp Innovations Ltd | Verbindungen für die behandlung von gewichtsverlust |
| ES2384641T3 (es) | 2005-07-14 | 2012-07-10 | Lithera, Inc. | Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo |
| GB0624282D0 (en) | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
| EP2646012A4 (en) * | 2010-11-24 | 2014-12-10 | Neothetics Inc | MONOTHERAPEUTIC FORMULATIONS OF SELECTIVE, LIPOPHILIC AND PROLONGED BETA AGONISTS AND METHODS OF COSMETIC TREATMENT OF SILHOUETTE ADPOSITY AND REINFORCEMENT |
| RU2695649C2 (ru) * | 2014-08-05 | 2019-07-25 | Раквалиа Фарма Инк. | Производные серина в качестве агонистов грелиновых рецепторов |
| US11400060B2 (en) * | 2020-01-13 | 2022-08-02 | Astromedical Biotechnology, Ltd. | Use of ketamine in the treatment of cachexia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE149089T1 (de) | 1987-09-15 | 1997-03-15 | Rowett Research Inst | Anwendungsgebiete von beta-adrenergenen agonisten |
| CA2481390C (en) * | 2002-04-12 | 2012-11-27 | Elan Pharma International Ltd. | Nanoparticulate megestrol formulations |
| US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
| ES2245612B1 (es) * | 2004-06-29 | 2007-08-16 | Universidad De Barcelona | Nuevo uso terapeutico del formoterol. |
| US8080528B2 (en) * | 2005-12-22 | 2011-12-20 | The Releef Initiative | Compositions and methods for treatment of cachexia |
| US7947579B2 (en) * | 2006-02-13 | 2011-05-24 | Stc.Unm | Method of making dense, conformal, ultra-thin cap layers for nanoporous low-k ILD by plasma assisted atomic layer deposition |
-
2008
- 2008-04-24 WO PCT/GB2008/001452 patent/WO2008129308A2/en not_active Ceased
- 2008-04-24 NZ NZ580975A patent/NZ580975A/xx not_active IP Right Cessation
- 2008-04-24 ES ES08737103.5T patent/ES2592289T3/es active Active
- 2008-04-24 EP EP08737103.5A patent/EP2155180B1/en not_active Not-in-force
- 2008-04-24 BR BRPI0810461-1A2A patent/BRPI0810461A2/pt not_active IP Right Cessation
- 2008-04-24 CN CN200880012990A patent/CN101730547A/zh active Pending
- 2008-04-24 AU AU2008240379A patent/AU2008240379B2/en not_active Ceased
- 2008-04-24 US US12/594,985 patent/US8653052B2/en not_active Expired - Fee Related
- 2008-04-24 JP JP2010504834A patent/JP5627452B2/ja not_active Expired - Fee Related
- 2008-04-24 EA EA200970957A patent/EA018918B1/ru not_active IP Right Cessation
- 2008-04-24 CN CN201410490740.8A patent/CN104306381A/zh active Pending
- 2008-04-24 CA CA2721739A patent/CA2721739C/en not_active Expired - Fee Related
- 2008-04-24 DK DK08737103.5T patent/DK2155180T3/en active
- 2008-04-24 KR KR1020097024247A patent/KR101546977B1/ko not_active Expired - Fee Related
- 2008-04-24 MX MX2009011294A patent/MX2009011294A/es active IP Right Grant
-
2009
- 2009-10-11 IL IL201426A patent/IL201426A/en not_active IP Right Cessation
-
2015
- 2015-03-19 HK HK15102807.2A patent/HK1202262A1/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210819T1 (hr) | Fenfluramin za uporabu u liječenju dravet sindroma | |
| JP2010510212A5 (enExample) | ||
| WO2009049184A9 (en) | Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors | |
| FR2926553B1 (fr) | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique | |
| JP2017178948A5 (enExample) | ||
| IL249165A0 (en) | Use of an antigen-mhc complex to prepare drugs for the prevention and treatment of autoimmune conditions | |
| JP2016539134A5 (enExample) | ||
| CL2013001654A1 (es) | Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| CL2007002513A1 (es) | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. | |
| CL2007002207A1 (es) | Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma. | |
| EP4342540A3 (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| BRPI0806531A2 (pt) | Composto, composição farmacêutica, agente terapêutico, e, uso do composto. | |
| IL209121A (en) | Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases | |
| WO2007101224A3 (en) | Inhibitors of the unfolded protein response and methods for their use | |
| CL2007002708A1 (es) | Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros. | |
| IL199945A (en) | Hydrochloric acid derivatives, pharmaceuticals containing them and their use in the preparation of drugs | |
| CL2012003340A1 (es) | Composicion farmaceutica de administracion oral de bendamustina y su uso en el tratamiento oral de una condicion medica seleccionada de leucemia linfocitica cronica, cancer de mama, entre otras. | |
| ZA201206360B (en) | Solid composition for the oral administration of dyes and diagnostic use thereof | |
| EP2015740A4 (en) | NEW LOW-DOSED PHARMACEUTICAL COMPOSITIONS WITH NIMESULID, PREPARATION AND USE | |
| EP2925340A4 (en) | Pharmaceutical compositions and therapeutic methods of use comprising selective agonists of melanocortin 1 receptor | |
| HK1220136A1 (zh) | 治疗b2-缓激肽受体介导的血管性水肿的方法 | |
| JP2012516348A5 (enExample) | ||
| WO2009013237A3 (en) | Stable solid pharmaceutical composition comprising candesartan or pharmaceutically acceptable forms thereof | |
| CL2008000965A1 (es) | Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor. | |
| JP2016507570A5 (enExample) |